Dr. J Thaddeus Beck, FACP, MD

Dr. Beck practices at Highlands Oncology Group PA in Rogers, Arkansas.

Dr. Beck's NPI, 1952372120, was assigned on January 27, 2006. Dr. Beck graduated from University of Arkansas For Medical Sciences College of Medicine in 1985. Dr. Beck holds Arkansas license C6790.

Dr. Beck's primary practice is Highlands Oncology Group PA, at 808 S 52nd St, Rogers, AR 72758 in Benton County. The practice phone is (479) 587-1700.

Dr. Beck's primary practice is Highlands Oncology Group PA in Rogers, Arkansas. Dr. Beck is also affiliated with Mercy Hospital Northwest Arkansas. The medical group on file is Highlands Oncology Group. Dmand AI also links Dr. Beck to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Beck practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Beck's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Beck is board certified in internal medicine by the American Board of Internal Medicine. Dr. Beck is licensed in Arkansas.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, immune deficiency disease, lung cancer, lymphedema and lymphoma among the conditions Dr. Beck treats.

CMS data shows 172,518 Medicare services from Dr. Beck across 112 procedure codes in 2024, for 1,460 Medicare patients. Medicare paid $2,536,018 for them.

CMS counts 1,460 Medicare patients who saw Dr. Beck in 2024. The largest group is 65 to 74, with 665 patients. 74% of them have high blood pressure, and 65% have high cholesterol. 7% are also on Medicaid. Their average risk score is 1.98, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Beck's median patient age at 67, with 63% women.

In 2024, Dr. Beck wrote 1,987 Medicare Part D claims for 383 patients. 84% of them were for generic drugs. CMS names the drug for 1,624 of them, across 47 drugs with 11 or more claims each, at $3,171,307 in total drug cost. In 2023, CMS named 1,572 claims across 41 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Beck for performance year 2024, reported as part of a group. Dr. Beck accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 45 papers to Dr. Beck, published from 2011 to 2024. 2021 was the busiest year, with 5. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Lung Neoplasms and Breast Neoplasms. Dr. Beck has published most often in Ann Oncol. Dr. Beck's most frequent co-authors are Melinda Lee Telli, MD, Aditya Bardia, MD and Lowell L. Hart, MD.

Dmand AI links Dr. Beck to 40 clinical trials, 11 of them phase 3 studies. 14 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Carcinoma, Bronchogenic. Eli Lilly and Company sponsors the most, 11. Open Payments lists research payments to Dr. Beck that name 11 trials.

CMS Open Payments shows 809 general payments to Dr. Beck from 72 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 40% of the total. Pfizer Inc. paid the most, $13,025. It also lists 58 research payments totaling $159,526 from 2016 to 2025, naming 11 clinical trials.

Dmand AI lists 1 award for Dr. Beck, most recently CMS Stage 1 EHR in 2012.

Dr. Beck graduated from University of Arkansas For Medical Sciences College of Medicine in 1985. Dr. Beck is a member of AOA, ACP, ASCO and ASH.

Dr. Beck is in network with 20 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 14. Check the plan with the practice before a visit.